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ABSTRACT
Introduction Living with and beyond a diagnosis of a 
low- and intermediate- grade glioma (LIGG) can adversely 
impact many aspects of people’s lives and their quality 
of life (QoL). In people with chronic conditions, self- 
management can improve QoL. This is especially true 
if people are supported to self- manage. Supported 
self- management programmes have been developed for 
several cancers, but the unique challenges experienced 
by LIGG survivors mean these programmes may not be 
readily transferable to this group. The Ways Ahead study 
aims to address this gap by exploring the needs of LIGG 
survivors to develop a prototype for a supported self- 
management programme tailored to this group.
Methods and analysis Ways Ahead will follow three 
sequential phases, underpinned by a systematic review 
of self- management interventions in cancer. In phase 1, 
qualitative methods will be used to explore and understand 
the issues faced by LIGG survivors, as well as the barriers 
and facilitators to self- management. Three sets of 
interviews will be conducted with LIGG survivors, their 
informal carers and professionals. Thematic analysis will 
be conducted with reference to the Theoretical Domains 
Framework and Normalisation Process Theory. Phase 
2 will involve co- production workshops to generate 
ideas for the design of a supported self- management 
programme. Workshop outputs will be translated into a 
design specification for a prototype programme. Finally, 
phase 3 will involve a health economic assessment to 
examine the feasibility and benefits of incorporating the 
proposed programme into the current survivorship care 
pathway. This prototype will then be ready for testing in a 
subsequent trial.
Ethics and dissemination The study has been reviewed 
and approved by an National Health Service Research 
Ethics Committee (REC ref: 20/WA/0118). The findings 
will be disseminated through peer- reviewed journals, 
conference presentations, broadcast media, the study 
website, The Brain Tumour Charity and stakeholder 
engagement activities.
INTRODUCTION
Each year in the UK, more than 10 000 new 
primary brain tumours are diagnosed. Over 
the past 40 years, survival has doubled; 5- year 
survival is now 60% for those aged 15 to 39 
years at diagnosis and 35% for those aged 40 
to 49 years. These trends mean that there is 
a growing population of people, in partic-
ular younger adults, living with and beyond a 
primary brain tumour diagnosis.1
A brain tumour can have a devastating 
impact on an individual’s life, and many 
Strengths and limitations of this study
 ► Ways Ahead will develop an evidence- based and 
theoretically- informed supported self- management 
programme specifically designed to improve quality 
of life in adult primary brain tumour survivors.
 ► The methodological approach benefits from the 
use of recognised frameworks for systematic in-
tervention development, and the incorporation of 
key stakeholder perspectives through all stages of 
intervention development, to optimise programme 
relevance, acceptability, usability and feasibility.
 ► The inclusion of an economic assessment at the de-
velopment stages affords the opportunity to consid-
er how the programme might integrate with existing 
pathways and to optimise its efficiency.
 ► The outcome of the study will be a prototype pro-
gramme ready to be taken forward for testing. In the 
meantime, dissemination of findings may stimulate 
survivors to initiate new self- management strate-
gies and encourage clinical teams to place greater 
emphasis on supporting self- management in brain 
tumour follow- up.
 ► While the findings will be specifically applicable to 
those with low- and intermediate- grade gliomas, 
some may be generalisable to other groups with 
brain tumours.
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of the problems and needs are specific to this form of 
cancer. Patients can experience a range of common 
cancer- related symptoms (e.g. fatigue, sleep disorders and 
pain) as well as others specifically related to the tumour 
and its treatment (e.g. cognitive limitations, seizures, 
visual impairment, changes in personality and behaviour, 
speech problems and mobility problems).2–4 These symp-
toms can occur in clusters and get worse as the disease 
progresses.5–7 Cognitive deficits, in particular, increase as 
the disease progresses, hampering communication and 
decision- making.6 This can contribute to changing social 
roles, loss of independence and isolation.4 Patients often 
experience significant distress, depression and anger.8–10 
These, in turn, adversely impact physical and psychoso-
cial quality of life (QoL).11 12
As a result of the tumour, its treatment and treat-
ment side- effects, those living with a brain tumour often 
have multi- faceted and complex supportive care needs. 
However, these needs often go unmet, in part due to poor 
communication with, and information from, healthcare 
providers, as well as low referral to and use of psychosocial 
services.6 13 14 Given this burden, it is essential to identify 
effective ways to empower and support adults living with 
a primary brain tumour to manage the specific problems 
that they face, adjust to life after treatment, and optimise 
their well- being and QoL.
Self- management is an ‘individual’s ability to manage 
the symptoms, treatment, physical and psychosocial 
consequences and lifestyle changes inherent in living 
with a chronic condition’.15 There is a large and 
growing evidence base indicating that self- management 
programmes can improve various clinical and psycho-
social outcomes—including QoL, psychological well- 
being and healthcare utilisation—in people with 
long- term conditions.16 However, to successfully self- 
manage, patients need a set of skills (such as problem 
solving, action planning/goal setting and communi-
cating with healthcare providers) as well as the moti-
vation and confidence to manage their condition. 
Self- management interventions seek to equip people 
with these skills and confidence, usually by improving 
self- efficacy.17
Self- management is not—and should not be—the sole 
responsibility of the patient.18 They need support from a 
network of health professionals, family and friends, and 
fellow patients.19 Thus, self- management programmes 
must consider what health professionals and health 
services can do to support people to self- manage, and 
how best to mobilise social resources.20 Indeed, self- 
management strategies co- created with patients and 
providers are more likely to have positive effects.16
There is emerging evidence that both problem- focussed 
and adjustment- focussed programmes can improve 
cancer survivors’ self- efficacy, social, physical and psycho-
logical well- being, and QoL.21–26 However, the potential 
for self- management in adults living with a primary brain 
tumour has not been well investigated. The unique and 
complex needs of this group means that programmes 
developed for other conditions or cancers are unlikely to 
be suitable or easily transferable.
AIMS AND OBJECTIVES
Aim
The aim of the Ways Ahead study is to design an 
evidence- based and theoretically- informed supported 
self- management programme to improve QoL in adults 
living with a specific form of brain tumour—low- and 
intermediate- grade glioma (LIGG).
Objectives
The objectives of the Ways Ahead study are to:
1. Identify the characteristics and components of success-
ful self- management interventions that have been test-
ed in adult cancer survivors.
2. Identify self- management strategies currently used by 
people living with LIGGs.
3. Explore individual- level barriers to, and enablers of, 
self- management by people living with LIGGs.
4. Identify health system/service- level factors that would 
help or hinder implementation of a supported self- 
management programme for people living with LIGGs.
5. Co- produce a prototype for a supported self- 
management programme with survivors, informal car-
ers and professionals.
6. Estimate the potential costs and benefits of imple-
menting a supported self- management programme for 
LIGG survivors, and assess how this programme would 
change the current survivorship care pathway.
METHODS AND ANALYSIS
Overview of study design
Ways Ahead is a 3- year multi- method study (2019 to 
2022), involving three sequential phases, underpinned 
by a systematic review (figure 1). We are following estab-
lished frameworks for the systematic development of 
interventions.27 28 In the first phase, three sets of semi- 
structured interviews will be conducted with patients, 
informal carers and professionals. These will identify 
barriers to, and enablers of, self- management, as well as 
self- management strategies currently used by people with 
LIGGs. The second phase will include co- production 
activities (namely workshops), in accordance with the 
sequential and systematic co- design approach of O’Brien 
et al.29 These workshops will integrate evidence, expert 
knowledge and experience, and stakeholder involvement 
to develop a prototype for a supported self- management 
programme. For the third phase, an economic model of 
current care pathways will be developed and extended to 
incorporate the proposed supported self- management 
programme, to assess its acceptability and feasibility. 
These three phases will be underpinned by an updated 
systematic review of components and characteristics of 
supported self- management interventions which have 
been tested among adults living with cancer.
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Table 1 summarises how the activities for each inter-
view set and co- design workshop will be tailored to the 
different samples involved in this study.
Systematic review
The review, which has been registered with PROSPERO 
(CRD42019154115), will follow PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses) guidelines.30
MEDLINE/Embase, CINAHL, PsycINFO, Cochrane 
Database of Systematic Reviews and Scopus will be 
searched for papers published in English, which evaluate: 
an intervention which is described as self- management 
or as seeking to develop self- management skills; targeted 
at adults diagnosed with cancer; during the survivorship 
phase (i.e. after completion of primary treatment and 
not at end- of- life); studies using design with a compar-
ator (eg, controlled trials, feasibility or pilot studies with 
control groups, and pre–post design) will be eligible.
Abstracts and titles will be sifted independently by 
two team members. Full texts of articles deemed poten-
tially eligible will be obtained and reviewed by two team 
members. Reference lists of eligible articles and rele-
vant reviews will be searched to identify any articles 
missed. Eligible studies will be assessed for risk of bias 
using the Critical Appraisal Skills Programme checklist 
for randomised studies,31 and the Joanna Briggs Insti-
tute tool for non- randomised studies.32 The TIDieR 
(Template for Intervention Description and Replication) 
Figure 1 Flowchart illustrating the phases of the Ways Ahead study.  o
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checklist will be used to describe the characteristics of 
the interventions; that is, systematically describe each 
intervention in terms of (i) mode of delivery (e.g. face- to- 
face or web- based); (ii) personnel delivering the support 
(e.g. healthcare professionals or lay educators); (iii) 
targeting (e.g. individually tailored or group- based); and 
(iv) intervention intensity, frequency and duration.33 The 
PRISMS (Practical Reviews in Self- Management Support) 
taxonomy18 will be used to abstract the self- management 
components of the interventions (e.g. information about 
condition/management, provision of equipment and 
social support). Data will be abstracted on health- related 
QoL (HRQoL), self- efficacy, as well as any other primary 
outcomes and any health economic outcomes. Narrative 
synthesis of eligible studies will be undertaken together 
with—if appropriate—meta- analysis, undertaken in 
RevMan, to identify which components or characteristics 
of the interventions are associated with improved HRQoL 
and self- efficacy.
Target population
The Ways Ahead study will focus on LIGGs, which are 
most commonly diagnosed in young adults in their 30s 
and 40s.34–37 In almost all cases, LIGGs will progress to 
high- grade gliomas or recur: they are rarely cured.38 
Consequently, life expectancy following diagnosis with a 
LIGG is limited to around 5 to 15 years, depending on the 
subtype.36 37 39 Living for extended periods with a terminal 
condition can affect people’s ability to recuperate, cope 
with and resume everyday activities such as returning 
to work.40 Therefore, the development of a supported 
self- management programme is likely to be particularly 
beneficial for this patient group, but to achieve this, their 
distinct experiences and needs must be understood.
Setting and eligibility criteria
Ways Ahead will be conducted in partnership with 
several National Health Service (NHS) trusts, including 
Newcastle upon Tyne Hospitals NHS Foundation Trust, 
Leeds Teaching Hospitals NHS Trust, The Christie NHS 
Foundation Trust, Salford Royal NHS Foundation Trust, 
South Tees Hospitals NHS Foundation Trust, Guy’s and St 
Thomas’ NHS Foundation Trust and NHS Lothian. The 
study will also collaborate closely with The Brain Tumour 
Charity.
Table 2 summarises the inclusion criteria for partici-
pants in each interview set.
In accordance with Dworkin’s sample size policy,41 each 
interview set will likely require 25 to 30 participants for 
reasonable saturation, though this cannot be entirely pre- 
determined ahead of analysis.42 Purposive sampling strata 
will be defined for each interview set to ensure sample 
Table 1 Summary of data collection activities for phases 1 and 2
Phase (component) Description
P1 (patients) The survivor topic guide will cover: the impact of the brain tumour on health and well- being; 
understanding and views of self- management; self- management strategies currently and previously 
used by the individual; other self- management strategies the individual might like to, or be willing to 
use; experience of formal and informal support for self- management; difficulties experienced with, and 
barriers to, self- management; and what would help the individual better self- manage.
P1 (informal carers) The informal carer topic guide will cover: their views and attitudes towards self- management for their 
support recipient; their contributions to support the recipient’s self- management; and barriers and 
facilitators to support the recipient self- managing.
P1 (professionals) The professionals’ topic guide will cover: views on main areas of unmet needs among LIGG survivors; 
potential for self- management among LIGG survivors; own experiences of patients who have used self- 
management; and what would be needed to successfully deliver supported self- management for LIGG 
survivors.
P2 (workshop A) Workshop A with survivors and informal carers will generate ideas for what is needed to improve self- 
management in LIGG survivors and what support would be useful. Potential activities include presenting 
evidence statements based on the systematic review and phase 1, asking participants to review and 
prioritise these. To generate intervention design ideas, personas66 (‘characters’ representing different 
people affected by LIGG) will be generated prior to the workshop. Workshop participants will be asked 
to consider what an intervention for each specific persona might involve (components, mode of delivery 
and so on). De Bono’s ‘Six hats’ approach67 may also be used to encourage participants to reflect on 
the needs and perspectives of patients, informal carers and professionals.
P2 (workshop B) Workshop B with professionals and other stakeholders will follow a similar format to workshop A, 
and develop the ideas generated by survivors and informal carers. Participants will also discuss the 
feasibility of implementing the concepts from workshop A into current care pathways.
P2 (workshop C and 
D)
Workshop C and, if needed, D, with survivors, informal carers, professionals and stakeholders will seek 
participant feedback on supported self- management programme prototypes, developed following 
workshops A and B. Participants will discuss potential challenges around acceptability and feasibility of 
survivors’ effectively engaging with the programme.
LIGG, low- and intermediate- grade glioma.
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heterogeneity and elicitation of a broad range of views 
and experiences. The sampling strata for survivors and 
informal carers will be: time since diagnosis; treatment 
modality(ies); and gender. The sampling strata for profes-
sionals will be the clinical centre and discipline. We will 
also seek a maximum diversity sample of other profes-
sionals, in terms of organisation and role.
For phase 2, we will seek diversity among co- production 
workshop participants.
Recruitment procedures
Recruitment of survivors: phase 1
Identification and recruitment of survivors will happen 
in collaboration with healthcare professionals within the 
collaborating sites. Depending on site preference, two 
processes may be used.
Recruitment process 1: Potentially eligible survivors will be 
identified from their medical records and provided with 
an information sheet and reply slip, either face- to- face at 
a clinic visit, or by post. If the individual would like to 
take part or find out more information, they can return 
the reply slip to a member of clinic staff or post it to the 
study coordinator, and give permission for their contact 
details to be passed onto the study team or contact the 
study coordinator directly.
Recruitment process 2: Survivors may also be recruited via 
follow- up clinics. Information packs will be sent out, as 
above. Survivors will be informed that, at their next clinic 
visit, the researcher will be present and with their permis-
sion, will tell them more about the study and answer any 
questions. During the clinic conversation, the individual 
will be asked if they would be happy to take part and, if so, 
the interview will be scheduled. If they require more time 
to consider, the co- ordinator will telephone them in a few 
days for a final decision.
Recruitment of informal carers: phase 1
Survivors who have been interviewed will be asked to 
nominate someone who has been involved in helping 
care for/support them since diagnosis. The study team 
will provide the survivor with a carer study pack and ask 
them to pass it on to the carer. Informal carers may also 
be identified through collaborating sites, as healthcare 
professional sometimes know carers from their atten-
dance to support a patient at a clinic visit.
Other recruitment routes for survivors and carers
If required, we will also use other routes to recruit patients 
and informal carers, including advertising through The 
Brain Tumour Charity’s Research Involvement Network 
(RIN) and on the Ways Ahead study website. We may 
also post on relevant online forums and social media 
platforms.
Recruitment of professionals: phase 1
Healthcare professionals who are members of the brain 
cancer multidisciplinary teams at collaborating sites will 
be invited to interview. Those interested will be asked 
to call, email or return a reply slip using a prepaid enve-
lope to the study team. We will also promote the study 
through The Brain Tumour Charity healthcare profes-
sional network and invite potentially interested health-
care professionals to contact the study coordinator by 
email or telephone.
Cancer support professionals will be identified through 
patient support organisations or charities (i.e. Maggie’s 
Centre Newcastle, Brain Tumour Support, and The Brain 
Tumour Charity). We will write inviting them to be inter-
viewed, with an information sheet attached. We will also 
allow for snowball sampling among this group.
Recruitment to phase 2
Recruitment for phase 2 co- production workshops will 
follow the same routes as phase 1. Participants from phase 
1 will be invited to register their interest in taking part in 
phase 2, but we will also seek to include some survivors, 
Table 2 Summary of eligibility criteria for each participant 
group
Group Eligibility criteria
Patients  ► Aged 18 years or older
 ► In remission or stable on a watchful 
waiting approach
 ► Have a grade II astrocytoma, or a grade 
II or III oligodendroglioma
 ► Have completed primary treatment (or be 
on observation)
Exclude if they:
 ► Have severe psychological or social 
problems
 ► Have communication difficulties, 
cognitive impairment or memory 
difficulties so significant that they are 
unable to take part
 ► Are non- English speaking
Informal carers  ► Aged 18 years or older
 ► Currently support, or have supported 
in the past 5 years, someone with 
LIGG (the index survivor need not have 
participated)
Professionals  ► Are a member of a relevant 
multidisciplinary team, involved in the 
care of brain tumour patients
 ►  Including, but not limited to, medics, 
nurses and allied health professionals
 ► OR Are involved in the support of brain 
tumour survivors outside of NHS care 
pathways
 ►  Including, but not limited to, 
counsellors, benefits advisers and social 
workers
LIGG, low- and intermediate- grade glioma; NHS, National Health 
Service.
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informal carers and professionals who did not take part 
in phase 1.
Procedures
Table 1 provides a summary of the topics covered in each 
interview set, as well as the content of each workshop.
Phase 1: semi-structured interviews
Interviews will be conducted by research staff and take 
place either by phone, video call or face- to- face. Inter-
views will occur at a time and place convenient for the 
interviewee. Where possible, survivors and their informal 
carers will be interviewed separately so that each can be 
fully open and honest. Each interview is expected to last 
60 to 90 minutes, or as long as the participant wishes. 
Once consent has been obtained, each participant will 
complete an ‘About you’ form, to collect some key demo-
graphic details such as age, education and employment 
status. The demographic questions asked vary appropri-
ately for the survivors, informal carers and professionals.
Interviews will be informed by topic guides, which will 
be used flexibly to allow interviewees to raise issues they 
consider important. The interviewer will ask ‘headline’ 
open- ended questions for each area of interest on the 
topic guide; probes will then be used to explore issues in 
more depth. The topic guide may evolve as the interviews 
progress to examine emerging themes.
Phase 2: co-production workshops
Each workshop will take place in a neutral location and will 
be facilitated by members of the study team. It is expected 
that each workshop will last approximately 3 hours. Care 
will be taken to make sure participants understand that 
discussions taking place within the workshop are confi-
dential. The researchers will ensure an atmosphere which 
is welcoming and non- judgemental, and it will be clear 
that all participants are treated as equals. Several activ-
ities will be used at each workshop (table 1) to engage 
participants, ensure workshops are interactive and inter-
esting, and to facilitate discussion and interaction among 
participants.
Planned analysis
Analysis of the phase 1 interviews will occur in parallel 
with data collection to ensure that any new issues raised 
are explored in subsequent interviews. The first few inter-
views in each set will be independently coded by two team 
members, who will discuss and arrange the emerging 
codes and themes to be applied to the remainder of the 
interview set. Each interview set will be analysed sepa-
rately using both inductive and deductive approaches. 
For inductive analysis, thematic analysis, within the frame-
work approach, will be used.43–45 For the more deductive 
phases, self- management strategies used by survivors and 
informal carers will be identified and classified following 
Yun et al46 and Dunne et al.47 The Theoretical Domains 
Framework (TDF)48 will also be used to identify which 
domains influence the self- management behaviours of 
people with LIGG.
Normalisation Process Theory (NPT)49 will be used 
to aid the analysis of professional interviews. This will 
identify key service/system issues, which might help or 
hinder implementation of a supported self- management 
programme. For analytical rigour, the classification of 
self- management strategies, belief statements to the 
TDF domains, and NPT constructs will be discussed and 
agreed within the team.
Findings from the interviews and the systematic review 
will be combined into a ‘theoretical model’ of supported 
self- management in LIGGs. This will identify which influ-
ences on self- management are potentially modifiable to 
determine what needs to be done to change survivors’ 
self- management behaviours. The behaviour change 
wheel (BCW)50 will be used to map the TDF domains 
within the theoretical model onto intervention functions 
that might be effective in changing self- management 
behaviours. Associated behaviour change techniques 
(BCT) will be identified from the BCT taxonomy,51 that 
is, the techniques that can be used to overcome barriers 
to, and enhance enablers of, self- management.
As regards phase 2, the workshop outputs will be criti-
cally examined and evaluated to generate a design brief 
and intervention specification. This will detail the aim of 
the intervention, the design features it will include and 
how these will be operationalised, overall constituting the 
prototype intervention. A logic model, including a graph-
ical and textual representation of how the intervention is 
intended to work, linking outcomes with processes and the 
underlying theoretical assumptions will be developed.52
Phase 3: health economic assessment
An early- stage health technology assessment will be 
undertaken to assess the feasibility of the prototype inter-
vention. This will involve developing an Excel- based 
economic model that compares resource utilisation and 
outcomes from the routine survivorship care pathway 
(i.e. standard of care) with the proposed intervention. 
In order to understand the standard of care compar-
ator pathway, a pragmatic review of cancer survivorship 
literature will be undertaken and combined with expert 
elicitation techniques from a range of stakeholders. This 
will involve overlap with phase 1 and 2 data collection 
methods as well as further independent evidence gath-
ering, including focussed discussions or a brief survey with 
health professionals who care for patients with LIGGs.
The intervention pathway will include resource utili-
sation associated with the delivery and follow- up of the 
supported self- management programme. Expected 
clinical and QoL outcomes will also be included. The 
programme characteristics will be costed using a micro-
costing framework, itemising each identified compo-
nent of the implementation and sustainability of the 
programme. Resource utilisation consistent with the 
programme features will also be costed using national refer-
ence costing approaches. Expected changes to resource 
utilisation, and disease- specific and QoL outcomes will be 
explored through expert elicitation techniques guided by 
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available evidence on self- management programmes for 
cancer survivors.
The disaggregated costs and benefits of implementing 
the self- management programme, compared with the 
current care pathway will be analysed and reported, 
consistent with a cost- consequence analytical frame-
work. Costs will be reported in 2020 (£). A deterministic 
cost- effectiveness analysis will also be highlighted using 
average costs and effects across both the intervention 
and the current care pathways; the base case analysis will 
adopt an NHS healthcare payer perspective. Incremental 
cost- effectiveness ratios describing the ratio of cost differ-
ence to effectiveness difference for the range of outcomes 
identified will be estimated and reported for the base case 
analysis along with a series of sensitivity and scenario anal-
yses, including the adoption of a societal cost perspective. 
The net benefit of the intervention will also be examined 
and a summary of the drivers of uncertainty in costs and 
benefits will be presented.
Patient and public involvement
A patient and public involvement (PPI) panel comprising 
brain tumour survivors and informal carers who support 
a brain tumour survivor has been established. We have 
also consulted members of The Brain Tumour Charity’s 
RIN. Throughout Ways Ahead, patients will be consulted 
on the design and conduct of research activities, as well as 
the interpretation and dissemination of findings. To date, 
PPI input has been obtained on the protocol, study infor-
mation sheets (including appropriateness and sensitivity 
of language), topic guides and the study website.
As the project progresses, the panel will be invited to: 
comment and reflect on findings from the interviews; 
identify what they see as the key messages that need 
to be disseminated to survivors, informal carers and 
the public; co- design the lay summary of findings; and 
advise on other dissemination activities. They will also 
be invited to contribute to the design of the supported 
self- management programme (via the co- production 
workshops).
ETHICS AND DISSEMINATION
Ethics and safety
All data from the interviews and workshops will be treated 
with strict confidence, anonymised, password protected 
and stored in secure facilities at the Population Health 
Sciences Institute at Newcastle University. Detailed infor-
mation sheets will preface participation. Participants 
who provide informed consent (which will be written for 
face- to face interviews/workshops and audio- recorded 
when these take place remotely) and meet the inclusion 
criteria will be assigned a pseudonym. Any identifiable 
data will be stored securely behind the NHS firewall, 
using REDCap software, which is Health and Social Care 
Network (HSCN) compliant and only accessible to autho-
rised members of the study team.
Dissemination plan
Study findings will be prepared for a range of stake-
holder audiences. The study website has been established 
(https:// research. ncl. ac. uk/ waysahead/), which will be 
used to disseminate all outputs and materials.
For scientific dissemination, findings will be presented 
at relevant national and international conferences. Papers 
will be submitted to journals in neuro- oncology, cancer 
survivorship and psycho- oncology/behavioural science.
For lay dissemination, participants will have the option 
to receive a lay summary of the results. To reach patient 
and general populations, updates will be posted on the 
study website, with key messages (crafted together with 
the PPI Panel) highlighted. We will also embed podcasts 
within the website, with members of the team talking 
about the study, what it means and what survivors can 
do to self- manage. We will also seek to discuss the study 
findings with Brain and Central Nervous System Expert 
Advisory Groups in Cancer Alliances across different 
regions. Finally, we will hold a dissemination event for all 
stakeholders.
DISCUSSION
Little research has been conducted to understand people’s 
everyday experiences of living with and managing a 
LIGG. Previous research has tended to combine people 
with low- grade and high- grade gliomas.53–58 Since those 
with high- grade gliomas face different symptoms, signifi-
cantly shorter life- expectancy and tend to be older, 
these findings are insufficient to inform an interven-
tion aimed at LIGGs. To address this evidence gap, and 
inform the development of a supported self- management 
programme, this study will generate considerable empir-
ical data on the experiences of those living with a LIGG, 
both survivors and informal carers.
To date, self- management interventions in cancer have 
tended to focus on either breast or prostate cancer survi-
vors59 60—where prognosis is very good—or aimed, more 
broadly, at survivors of common types of cancer.61 Far 
less is known about the self- management needs resulting 
from cancers with more complex/challenging outcomes, 
such as those experienced by people with LIGGs. Argu-
ably, these groups need programmes specifically targeted 
to their complex needs and experiences, particularly 
since targeted self- management interventions have been 
found to be successful.62
It is also increasingly recognised that interventions 
which are systematically developed from the bottom- up, 
based on evidence and theoretically- informed are more 
likely to be effective.27 28 By adopting this approach in the 
Ways Ahead study, we will be able to identify the factors 
affecting a patient’s capacity to self- manage. From this, the 
theoretical constructs can be selected, and we can deter-
mine what BCTs are likely to be effective in addressing 
these constructs. Consequently, we can then evaluate why 
any behavioural changes have occurred in future testing 
of the prototype.
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The Ways Ahead study responds to NHS England’s 
recommendations that cancer patients be provided 
with information and education to prepare for self- 
management, including advice on healthy lifestyles, 
information on managing the long- term side effects of 
treatment, signposting to rehabilitation, work and other 
support services.63 The study is also consistent with the 
objectives of the National Cancer Survivorship Initia-
tive, which moved the focus of cancer care from treat-
ment delivery to recovery, health and well- being,64 and 
the English Cancer Strategy, which aspires to a recovery 
package being available to every person with cancer by 
2020.65
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